Eris Lifesciences Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Eris Lifesciences Q2 results FY27 announcement is the next scheduled earnings event for Eris Lifesciences Ltd., Eris Lifesciences Ltd is an Indian pharmaceutical company that manufactures and markets branded formulations across chronic therapy areas including diabetes, cardiology, dermatology, nephrology and CNS, alongside a domestic biosimilars and insulin business.. The stock traded at Rs 1,297.10 on the NSE on 16 September 2026, down 0.99% from the previous close of Rs 1,310.10, about 25.5% below its 52-week high of Rs 1,740.00 and 8.1% above its 52-week low of Rs 1,200.00.

What makes the Eris Lifesciences Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 792.00 crore of revenue and a profit of Rs 134.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 873.00 crore and a profit of Rs 143.00 crore. Everything below is built from those reported figures rather than from any forecast.

Click Here – Get Free Investment Predictions

When Is the Eris Lifesciences Q2 Results FY27 Date?

The Eris Lifesciences Q2 results date for FY27 is not confirmed. As of 16 September 2026, Eris Lifesciences Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.

What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Eris Lifesciences Q2 results date becomes public through that filing rather than through any advance announcement.

Also read – India Glycols Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

The Eris Lifesciences Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Eris Lifesciences.

Eris Lifesciences Q2 Results Expectations: What the Market Is Actually Tracking

No verified analyst estimate for the Eris Lifesciences Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Eris Lifesciences. The Eris Lifesciences Q2 results watchlist below is built from what the company has actually reported and disclosed.

Eris Lifesciences Q2 results for the September 2026 quarter are awaited against a backdrop of steady revenue growth over the last five reported quarters. Revenue moved from Rs 773 crore in June 2025 to Rs 792 crore in September 2025, Rs 807 crore in December 2025, dipped to Rs 757 crore in March 2026, and then rose to Rs 873 crore in June 2026, the highest of the five quarters. This gradual uptrend, interrupted by one softer quarter, is the base investors will use to frame Eris Lifesciences Q2 results expectations for the September 2026 quarter. No quarter in this window was loss-making, which keeps the revenue trajectory relatively easy to read even though the pace of growth has not been uniform quarter to quarter. As Eris Lifesciences Q2 results approach, this five-quarter revenue pattern, rather than any forward guidance, is the only verifiable reference point available.

Operating margin for Eris Lifesciences held in a narrow band through the five quarters feeding into Eris Lifesciences Q2 results, at 36% in June 2025, 36% in September 2025, 35% in December 2025, 36% in March 2026 and 34% in June 2026, a mild step down at the most recent print. Net profit tells a less even story: Rs 125 crore in June 2025, Rs 134 crore in September 2025, Rs 109 crore in December 2025, then a sharp jump to Rs 279 crore in March 2026 before settling back to Rs 143 crore in June 2026. That March 2026 figure is not representative of underlying performance, since profit before tax that quarter was only Rs 159 crore and profit was inflated by a large tax credit. Anyone comparing quarters ahead of Eris Lifesciences Q2 results should treat that figure as an outlier, and Eris Lifesciences Q2 results should be judged on the steadier margin trend instead.

On valuation, Eris Lifesciences trades at a trailing PE of around 27.6, with a book value near Rs 282 per share, return on equity of about 18.7%, return on capital employed near 14.1% and a dividend yield of roughly 0.54%, metrics that will frame how the market reacts to Eris Lifesciences Q2 results. The biggest data-quality caveat in the screener record is the March 2026 quarter, where net profit of Rs 279 crore looks disconnected from a profit before tax of just Rs 159 crore because of a large tax credit or deferred tax reversal that quarter, an anomaly investors should factor in rather than extrapolate. Aside from that one quarter, the five-quarter window shows consistently profitable results with no loss-making periods. Heading into the September 2026 quarter, Eris Lifesciences Q2 results will need to be read alongside this tax-driven distortion so the underlying operating trend is not confused with a one-off accounting effect.

Check Eris Lifesciences Ltd. Live Fundamentals on the Univest Screener

Eris Lifesciences Q2 Results Preview: The Q1 FY27 Actuals It Builds On

Eris Lifesciences Ltd. reported revenue of Rs 873.00 crore in Q1 FY27, up 12.94% from Rs 773.00 crore in Q1 FY26, and a profit of Rs 143.00 crore at the net level, up 14.40% from Rs 125.00 crore in Q1 FY26. These are reported actuals, not estimates.

Also read – Indiamart Intermesh Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

Sequentially, revenue was up 15.32% over the March 2026 quarter figure of Rs 757.00 crore, and net profit was down 48.75% from Rs 279.00 crore in Q4 FY26. Operating margin stood at 36.0% in Q1 FY27 against 36.0% in the September 2025 quarter, which is the comparison the Eris Lifesciences Q2 results print will be read against.

Q2 FY26 Base: The Comparison Eris Lifesciences Q2 Results FY27 Must Beat

Eris Lifesciences Ltd. reported revenue of Rs 792.00 crore and a profit of Rs 134.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Eris Lifesciences Q2 results preview.

Net profit in that base quarter was below the Rs 143.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a manageable level. Revenue of Rs 792.00 crore sits below the Rs 873.00 crore of the June 2026 quarter, which frames how much sequential movement the Eris Lifesciences Q2 results print needs to show growth.

Eris Lifesciences Quarterly Results Trend Over the Last Four Quarters

Quarter	Revenue (Rs Cr)	Net Profit (Rs Cr)
Q2 FY26 (Sep 2025)	792.00	134.00
Q3 FY26 (Dec 2025)	807.00	109.00
Q4 FY26 (Mar 2026)	757.00	279.00
Q1 FY27 (Jun 2026)	873.00	143.00

Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company's exchange filings, and they are the only basis this Eris Lifesciences Q2 results preview uses.

Revenue across those four quarters ranged from Rs 757.00 crore to Rs 873.00 crore, and net profit from Rs 109.00 crore to Rs 279.00 crore. That spread is the honest context for the Eris Lifesciences Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.

Key Factors That Could Shape Eris Lifesciences Q2 Results FY27

The Eris Lifesciences Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Eris Lifesciences has already reported.

Valuation Snapshot

Eris Lifesciences trades at a trailing PE of about 27.45 with an EPS of roughly Rs 47.25, against a book value near Rs 282 per share, putting the price-to-book ratio at about 4.6. Return on equity stands at approximately 18.7%, a healthy figure for a pharmaceutical business of this scale, while the dividend yield is modest at around 0.54%. Together these numbers describe a moderately valued, profitable pharma company where the market is paying a premium to book value in exchange for a consistent return on equity, rather than pricing in exceptional near-term growth.

Technical and Price Context

Eris Lifesciences shares have traded between a 52-week low of Rs 1,200 and a 52-week high of Rs 1,740, and at a current price near Rs 1,297 the stock sits well off its yearly high while still comfortably above its yearly low. The stock is trading below both its 50-day moving average of about Rs 1,371 and its 200-day moving average of roughly Rs 1,407, suggesting the medium and longer-term trends are currently softer than the stock's own recent history. The relative strength index of around 45.82 sits in neutral territory, indicating neither strong buying nor selling pressure at current levels.

Balance Sheet and Payout

Eris Lifesciences carries a debt-to-equity ratio of about 0.6, a moderate level of borrowings for a pharmaceutical manufacturer that also runs a domestic biosimilars and insulin business requiring ongoing capital investment. The dividend yield of roughly 0.54% is modest, consistent with a company that has historically prioritized reinvestment and, in the past, acquisitions over large payouts. This balance sheet profile, a manageable amount of debt combined with a low but non-zero payout, is typical of a mid-sized pharmaceutical company still building out its chronic-therapy portfolio.

Eris Lifesciences Q2 Results FY27: Share Price and Valuation Going Into the Print

Eris Lifesciences share price today is Rs 1,297.10 on the NSE, down Rs 13.00 or 0.99% from the previous close of Rs 1,310.10 on 16 September 2026, ahead of the Eris Lifesciences Q2 results announcement.

Metric	Value (16 September 2026)
NSE Symbol	ERIS
Current Market Price	Rs 1,297.10
52-Week High	Rs 1,740.00
52-Week Low	Rs 1,200.00
Market Capitalisation	Rs 17975 crore
PE Ratio	27.45
PB Ratio	4.60
EPS (TTM)	Rs 47.25
Book Value per Share	Rs 282.00
Debt to Equity	0.60
Return on Equity	18.7%
50-Day Moving Average	Rs 1371.28
200-Day Moving Average	Rs 1406.87
RSI (14)	45.82

The stock trades below both its 50-day average of Rs 1371.28 and its 200-day average of Rs 1406.87, with a 14-day RSI of 45.82. None of this is a view on where the shares go once the Eris Lifesciences Q2 results are announced, and no price target is offered here.

Download the Univest iOS App or Univest Android App to track Eris Lifesciences Ltd. live price and quarterly earnings updates.

What Investors Should Watch When Eris Lifesciences Q2 Results Are Announced

Four lines carry most of the information in a company of this size, and reading them in order keeps the Eris Lifesciences Q2 results print in proportion.

1. Revenue against the Rs 792.00 crore reported in the September 2025 base quarter
2. Net profit against a profit of Rs 134.00 crore in that same quarter
3. Operating margin against 36.0% in Q1 FY27
4. Any exceptional item, provision or one-off gain disclosed alongside the numbers

A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Eris Lifesciences Q2 results announcement should be read together with the notes to the results rather than the headline alone.

Conclusion on Eris Lifesciences Q2 Results FY27

The Eris Lifesciences Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Eris Lifesciences Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.

On that basis the Eris Lifesciences Q2 results FY27 print faces a base of Rs 792.00 crore in revenue and a profit of Rs 134.00 crore, with the most recent quarter having delivered Rs 873.00 crore and a profit of Rs 143.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Eris Lifesciences, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.

FAQs on Eris Lifesciences Q2 Results FY27

What is the Eris Lifesciences Q2 results date for FY27?

Ans. The Eris Lifesciences Q2 results date for FY27 is not confirmed. Eris Lifesciences Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.

What quarter do the Eris Lifesciences Q2 results 2026 cover?

Ans. The Eris Lifesciences Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Eris Lifesciences Ltd. reports revenue, operating profit and net profit for that period, and the Eris Lifesciences Q2 results filing also carries the notes to the accounts.

What were the Eris Lifesciences Q1 FY27 results?

Ans. Eris Lifesciences Ltd. reported revenue of Rs 873.00 crore in Q1 FY27 and a profit of Rs 143.00 crore at the net level. Revenue was up 12.94% versus Q1 FY26 and net profit was up 14.40% from Rs 125.00 crore in Q1 FY26.

What were Eris Lifesciences Q2 FY26 results in the September 2025 quarter?

Ans. Eris Lifesciences Ltd. reported revenue of Rs 792.00 crore and a profit of Rs 134.00 crore in Q2 FY26. Operating margin was 36.0%. Those figures form the base for the Eris Lifesciences Q2 results FY27 comparison.

What are the main Eris Lifesciences Q2 results expectations this quarter?

Ans. No verified analyst estimate is publicly available. The Eris Lifesciences Q2 results expectations centre on revenue against the Rs 792.00 crore base, net profit against a profit of Rs 134.00 crore, operating margin against 36.0% in Q1 FY27, and any exceptional item disclosed with the numbers.

What is Eris Lifesciences share price today ahead of the Q2 earnings?

Ans. Eris Lifesciences share price is Rs 1,297.10 on the NSE as of 16 September 2026, down 0.99% from Rs 1,310.10. The stock is about 25.5% below its 52-week high of Rs 1,740.00 and 8.1% above its 52-week low of Rs 1,200.00, at a market capitalisation of Rs 17975 crore.

Is Eris Lifesciences a good stock to buy before the Q2 results?

Ans. This article does not offer a buy, sell or hold recommendation on Eris Lifesciences Ltd. The stock trades at a price-to-book ratio of 4.60 with a return on equity of 18.7%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.